Watch Now

Expo Summary

At a recent industry event, Southern Star Research’s experts Teresa Ringeri and David Fuller presented insights into the growing importance of the Asia-Pacific (APAC) region in oncology clinical trials. Their presentation, “APAC’s Strategic Advantage in Oncology Trials: Fast Start, Lower Cost, Global Impact,” highlighted why global biopharma companies are increasingly turning to the region for their early and late-phase studies.

Key points from the presentation include:

• Faster Study Start-Up: APAC countries, including Australia and South Korea, offer streamlined regulatory processes and strong institutional networks, enabling quicker site activation and patient recruitment.
• Cost Efficiency: Operational costs in APAC are significantly lower compared to the US and EU, without compromising trial quality or timelines.
• Global Relevance: The region’s diverse patient population, experienced investigators, and world-class infrastructure ensure that data from APAC trials are widely accepted by regulatory agencies worldwide.

Southern Star Research’s proven experience in managing complex oncology studies across APAC provides sponsors with a reliable partner to navigate the region’s regulatory and operational landscape. Our local expertise, combined with global trial oversight, ensures that oncology programs are delivered efficiently and with high data integrity.